Clopidogrel resistance
अंतिम अद्यतन 24 नवम्बर 2023
मरीज की संपादकीय दिशानिर्देशों
- डाउनलोडडाउनलोड
- साझा करें
- Language
- चर्चा
- Ask Patient
- ऑडियो संस्करण
- Google पर पसंदीदा स्रोतों में जोड़ें
Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cells called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).
के लिए वीडियो चयन आनुवंशिक स्थितियाँवीडियो लाइब्रेरी
विवरण
Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cells called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).
People with clopidogrel resistance who receive clopidogrel are at risk of serious, sometimes fatal, complications. These individuals may have another heart attack or stroke caused by abnormal blood clot formation; those with stents can develop blood clots (thromboses) within the stents, impeding blood flow.
People with clopidogrel resistance can be divided into two categories: intermediate metabolizers and poor metabolizers. Intermediate metabolizers are able to process some clopidogrel, so they receive partial benefit from the treatment but are not protected from developing a harmful blood clot. Poor metabolizers process little or no clopidogrel, so they receive very limited benefit from the treatment and are at risk of forming a harmful blood clot.
Clopidogrel resistance does not appear to cause any health problems other than those associated with clopidogrel drug treatment.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal codominant. More than one pattern can apply in different cases.
Related genes
Other names
CYP2C19-related poor drug metabolism
Poor metabolism of clopidogrel
Resistance to clopidogrel
Related patient information and medicines

Patient information leaflet
एंटीफॉस्फोलिपिड सिंड्रोम
Antiphospholipid syndrome is sometimes called Hughes' syndrome. Antiphospholipid syndrome (APS) - also called Hughes' syndrome - makes blood more likely than normal to clot (a thrombophilia Thrombophilia ). Clopidogrel Clopidogrel को रोकें blood clots , dipyridamole Dipyridamole to prevent blood clots and aspirin Aspirin to prevent blood clots.

Patient information leaflet
हृदय रोग
Treatments include the following: Medication Medicines are used to: Thin the blood and prevent blood clots forming in the heart and elsewhere in the body (eg, aspirin, clopidogrel, warfarin, apixaban) Improve blood flow to the heart (eg, nicorandil, ranolazine, ramipril) Slow down the heart rate if it is beating too fast (eg, bisoprolol,.

Patient information leaflet
टूटी या चोटिल पसलियाँ
You have a history of heart disease, stroke or peripheral ar... You have asthma, high blood pressure, kidney disease or may be pregnant. You are already taking aspirin (including low-dose aspirin Aspirin to prevent blood clots ) या clopidogrel Clopidogrel to prevent blood clots. You are taking these painkillers for long periods - say, for over two.

Patient information leaflet
क्षणिक इस्केमिक आक्रमण
A transient ischaemic attack (TIA) causes symptoms similar to a stroke. The most commonly used long-term antiplatelet medicine following a stroke or TIA is clopidogrel Clopidogrel to prevent blood clots. Sometimes, once a TIA or minor stroke has been diagnosed, people are offered a short course of two antiplatelet medications together (aspirin and.

Patient information leaflet
परिधीय धमनी रोग
Peripheral arterial disease, also called peripheral vascular disease, is a narrowing of the blood vessels (arteries). Surgery is only needed in ... Medicines A medicine called clopidogrel Clopidogrel to prevent blood clots is usually advised. This does not help with symptoms of PAD but helps to prevent blood clots (thromboses) forming in blood.

Patient information leaflet
एस्पिरिन और अन्य एंटीप्लेटलेट दवाएं
Most people who have a cardiovascular disease (for example, angina, peripheral arterial disease, or a previous heart attack, transient ischaemic attack (TIA) or stroke) take a low-dose aspirin (75 mg) each day or clopidogrel (75 mg) each day. For those with peripheral arterial disease (damage to the arteries in the legs), clopi... After a stroke.
अधिक पठन और संदर्भ
- Clopidogrel resistance; MedlinePlus, National Library of Medicine.
- Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 2013;28(1):28-37. doi: 10.2133/dmpk.dmpk-12-rv-085. Epub 2012 Nov 20.
- Niu X, Mao L, Huang Y, Baral S, Li JY, Gao Y, Xia YP, He QW, Wang MD, Li M, Zou L, Miao XP, Hu B. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2015 Apr;35(2):147-156. doi: 10.1007/s11596-015-1404-7. Epub 2015 Apr 16.
- Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
- Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members; Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed. Epub 2010 Jun 28. No abstract available.
- Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab. 2012 Oct;13(8):1196-204. doi: 10.2174/138920012802850146.
हमारे में दूसरों के साथ अपने विचार या अनुभव साझा करें रोगी समुदायों.
पेशेंट न्यूज़लेटर के लिए साइन अप करें
आपकी साप्ताहिक खुराक स्पष्ट, विश्वसनीय स्वास्थ्य सलाह की - जो आपको सूचित, आत्मविश्वासी और नियंत्रण में महसूस करने में मदद करने के लिए लिखी गई है।.
सदस्यता लेने पर आप हमारी स्वीकार करते हैं गोपनीयता नीति. आप किसी भी समय सदस्यता समाप्त कर सकते हैं। हम कभी भी आपका डेटा नहीं बेचते।.

